Bioprocessing Equipment Market Size & Forecast Report - 2025 to 2030

The global bioprocessing equipment market size was valued at around USD 63 billion in 2024 and anticipated to register a significant CAGR of over 9% during the forecast period from 2025 to 2030. The market is driven by the growing demand for biopharmaceuticals, including vaccines, monoclonal antibodies, cell & gene therapies, biosimilars, and recombinant proteins. As biologics continue to expand their share in the pharmaceutical pipeline, bioprocessing equipment—such as bioreactors, fermenters, filtration systems, chromatography systems, and disposable (single-use) technologies—plays a critical role in ensuring efficient production. Rising investments in biomanufacturing facilities, advancements in upstream and downstream processing, and the need for maintaining high product purity and yield are major factors propelling market growth. Additionally, the post-COVID emphasis on vaccine capacity and rapid biologics scale-up continues to accelerate equipment adoption globally.

The market is also undergoing a significant shift toward single-use systems, modular bioprocessing, and automation/AI-driven process control. These innovations help cut operational costs, reduce contamination risks, and improve flexibility, making them attractive to both established biopharma companies and CDMOs (Contract Development & Manufacturing Organizations). North America remains the leading region due to strong biotech infrastructure, while Asia-Pacific is rapidly emerging as a key growth hub driven by expanding biomanufacturing capabilities in China, India, and South Korea. As the therapeutic landscape moves further into personalized and advanced therapies, demand for scalable, cost-effective, and highly compliant bioprocessing equipment is expected to continue rising.

Key Insights:

• The market was valued at around USD 63 billion in 2024and experiencing a significant CAGR of over 9%
• Increasing demand for biologics, biosimilars, and cell & gene therapies is a major growth driver.
• Bioreactors remain the largest revenue-generating product category.
• Upstream processing accounts for the dominant share due to high investment in cell culture systems.
• North America leads the global market owing to strong biopharma infrastructure and R&D spending.
• Adoption of single-use bioprocessing systems is accelerating efficiency and lowering operational costs.
• Regulatory focus on quality, automation, and manufacturing compliance boosts equipment upgrades.
• Growing investments in continuous bioprocessing and advanced digital monitoring systems create new opportunities.
• Partnerships among biopharma companies and equipment manufacturers are increasing to expand production capacity.

Market Snapshot:

Bioprocessing Equipment Market Key Drivers:

The primary driver of the bioprocessing equipment market is the rapidly growing demand for biologics such as monoclonal antibodies, vaccines, biosimilars, and cell & gene therapies. As chronic and rare diseases increase globally, biopharmaceutical companies are expanding their production pipelines, which directly raises the need for advanced upstream and downstream equipment. Rising government funding, expansion of biomanufacturing facilities, and investments by CDMOs further strengthen market growth, especially as companies aim to scale production efficiently while maintaining high product purity and regulatory compliance.

Another major driving factor is the accelerating adoption of single-use technologies, modular systems, and automation-driven bioprocessing. These solutions reduce contamination risks, eliminate cleaning requirements, and offer superior flexibility — making them ideal for fast-changing biologics production environments. A recent industry update shows that 87% of biomanufacturers in 2025 increased their reliance on single-use bioreactors and disposable filtration systems, reflecting the industry’s shift toward faster, more adaptable, and lower-risk production workflows. As sustainability becomes important, manufacturers are also developing eco-friendly disposable components, further boosting the appeal and adoption of single-use bioprocessing equipment.

Industry Trends Fueling the Bioprocessing Equipment Market Growth:

Rapid Expansion of Single-Use Bioprocessing Technologies

Single-use systems (SUS) continue to transform the bioprocessing landscape, driven by their ability to deliver faster turnaround times, lower contamination risks, and greater operational flexibility. These disposable technologies—such as single-use bioreactors, mixers, sampling systems, storage bags, and filtration units—have become essential for multi-product and small-batch production, especially in biologics and vaccine manufacturing. Their plug-and-play characteristics allow companies to quickly scale up or scale out depending on production needs, making them a preferred choice for CDMOs and emerging biotech firms. In addition, the biopharmaceutical industry is increasingly focused on sustainability and waste reduction, which is pushing manufacturers to develop recyclable or bio-based materials for single-use components, further enhancing their appeal in a market shifting toward greener manufacturing practices.

Rising Adoption of Automation, AI, PAT, and Digital Bioprocessing

Automation and digital transformation have become core pillars of modern biomanufacturing. Facilities are integrating advanced software platforms, sensors, digital twins, and process analytical technology (PAT) to create highly controlled and data-driven environments. These tools support real-time process monitoring, predictive insights, automated batch adjustments, and minimized human error—critical for improving reproducibility and maintaining strict regulatory standards. AI-driven optimization models also help biomanufacturers simulate bioreactor conditions, anticipate equipment failures, and streamline upstream and downstream workflows. Digitalization is further enabling continuous bioprocessing, where materials flow uninterrupted through production steps, improving overall equipment effectiveness (OEE), reducing downtime, and lowering long-term operating costs.

Growth of Modular, Flexible, and Sustainable Manufacturing Platforms

Modular bioprocessing is gaining strong traction as companies seek faster facility deployment and greater flexibility to support advanced therapies, personalized medicines, and niche biologic products. Prefabricated cleanrooms, modular skids, and plug-and-produce systems allow organizations to expand capacity rapidly without the long construction timelines associated with traditional stainless-steel facilities. Sustainability is also becoming a central trend, with manufacturers increasingly committing to carbon-efficient operations and reduced material waste. A recent industry development highlights this movement: Thermo Fisher Scientific introduced plant-based bioprocessing containers made from renewable bio-based films, offering a lower-carbon alternative to traditional plastic components while maintaining standard performance and durability. This innovation reflects a broader shift across the industry as major players integrate eco-friendly materials into single-use equipment portfolios, aligning with global environmental goals while meeting the high-purity needs of biomanufacturing.

Future Opportunities Reshaping the Bioprocessing Equipment Market’s Evolution:

The bioprocessing equipment market presents significant opportunity in the expanding cell and gene therapy sector, where demand for specialized bioreactors, single-use consumables, and downstream purification technologies is surging. As more firms move toward personalized medicine, small-batch manufacturing, and clinical-scale production, there is a strong need for flexible, modular equipment that can scale efficiently without upfront heavy investments. This is especially true for CDMOs (Contract Development & Manufacturing Organizations), which can leverage disposable systems to offer cost-effective, lower-risk manufacturing solutions to biotech companies. In addition, rising government funding and R&D investments in biologics, particularly in emerging markets, are creating fresh demand for cutting-edge bioprocessing infrastructure.

Another compelling opportunity lies in the Asia-Pacific region, which is emerging as a major growth hub for biomanufacturing. The region is witnessing strong investments in bioprocessing capacity — particularly in upstream single-use bioreactors — driven by both domestic biopharma companies and global CDMOs. On the innovation front, in 2025, the Thermo Fisher Scientific’s launch of a 5 L DynaDrive single-use bioreactor (scalable up to 5,000 L) exemplifies how companies are expanding equipment portfolios to cater to both early-stage development and commercial scale manufacturing. This kind of product flexibility not only helps bioprocessing firms optimize development costs, but also strengthens the business case for adopting modular and scalable bioproduction platforms worldwide.

Bioprocessing Equipment Market Challenges:

The global bioprocessing equipment market faces several challenges, primarily centered around high capital costs, supply chain constraints, and technical complexity. Setting up bioprocessing facilities—especially those with advanced automation, single-use systems, and large-scale bioreactors—requires substantial investment, which can be a barrier for small and mid-sized biopharma companies. Supply chain issues, including shortages of critical single-use components and long lead times for specialized stainless-steel equipment, continue to disrupt production planning. Additionally, the market struggles with a global shortage of skilled bioprocessing professionals who can manage sophisticated upstream and downstream systems. Ensuring regulatory compliance across regions adds further pressure, as evolving GMP standards demand continuous upgrades in equipment validation, documentation, and quality assurance. These factors together create operational bottlenecks and increase the overall cost and complexity of biomanufacturing.

Market Segments Insights:

By Product Type: The Bioreactors Segment Dominated the Bioprocessing Equipment Market in 2024

The global bioprocessing equipment market is bifurcated into product type, process, application, end-user, and geography. On the basis of product type, the bioreactors segment dominated the market in 2024, primarily because bioreactors are the central equipment used to grow cells and produce biologics such as monoclonal antibodies, vaccines, recombinant proteins, and viral vectors. As demand for these therapies increases, biopharma companies and CDMOs are expanding bioreactor capacity across R&D, pilot-scale, and commercial production. The industry’s strong shift toward single-use bioreactors has accelerated this dominance by enabling faster changeovers, reducing contamination risks, and lowering cleaning and validation costs—making them ideal for multi-product and flexible manufacturing setups.

This segment also leads due to continuous technological advancements that enhance efficiency and scalability. Innovations such as intensified perfusion systems, integrated sensors, automation-enabled control, and modular, scalable single-use designs have made bioreactors indispensable in modern bioprocessing facilities. Their ability to support both traditional stainless-steel setups and next-generation continuous bioprocessing further strengthens their market leadership. As the biologics pipeline grows globally, bioreactors will remain the largest and most influential product category in the bioprocessing equipment market.

By Process Type: The Upstream Processing Sub-category Holds the Largest Share of the Global Bioprocessing Equipment Market

On the basis of process, the global bioprocessing equipment market is further segmented into upstream processing and downstream processing. As of 2024, the upstream processing segment dominates the market, driven by its central role in initiating and expanding biological production. Upstream operations involve cell culture, fermentation, media preparation, and environmental control—processes that require high-value equipment such as bioreactors, cell culture systems, mixing systems, and advanced monitoring technologies. The expanding demand for monoclonal antibodies, recombinant proteins, and cell & gene therapies has significantly increased the need for scalable and flexible upstream solutions. The rapid shift toward single-use bioreactors and perfusion-based systems has further accelerated growth, offering faster turnaround times, reduced contamination risks, and greater adaptability for multi-product facilities.

Upstream processing leads the market not only because of equipment importance but also due to continuous innovation that enhances productivity and efficiency at the earliest stages of biomanufacturing. Automation, real-time monitoring (PAT), AI-driven optimization, and high-density cell culture technologies are transforming upstream workflows, enabling higher yields with smaller footprints. Since every biologics manufacturing program begins with robust upstream development, companies prioritize investment here to ensure consistent, high-quality output downstream. As biologics pipelines expand globally, upstream processing will continue to account for the largest share of the bioprocessing equipment market.

The bioprocessing equipment market research report presents the analysis of each segment from 2020 to 2030 considering 2024 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2025 to 2030.

Historical & Forecast Period

• 2020-23 – Historical Year
• 2024 – Base Year
• 2025-2030 – Forecast Period

Global Bioprocessing Equipment Market Segmentation:

By Product Type:

• Bioreactors
• Filtration Systems
• Chromatography Systems Cell Culture Systems
• Mixing Systems
• Control & Monitoring Systems
• Others

By Process:

• Upstream Processing
• Downstream Processing

By Application:

• Vaccines
• Gene & Cell Therapy
• Monoclonal Antibodies (mAbs)
• Recombinant Proteins
• Others

By End-User:

• Biopharmaceutical Companies
• Contract Manufacturing Organizations (CMOs)
• Academic & Research Institutes

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: North America Leads the Global Bioprocessing Equipment Market

As of 2024, the North America dominated the global bioprocessing equipment market, primarily due to its highly developed biotechnology and biopharmaceutical ecosystem. The U.S. hosts many of the world’s leading biopharma companies, CDMOs, and research institutions, all of which drive continuous demand for advanced bioreactors, filtration systems, chromatography platforms, and single-use technologies. Strong government funding for biologics, robust clinical trial activity, and rapid adoption of automation and digital bioprocessing further strengthen North America’s leadership. The region also benefits from a mature regulatory framework, which pushes companies to invest in high-quality, compliant bioprocessing equipment.

In addition, North America leads due to ongoing expansions in biologics manufacturing capacity, especially for monoclonal antibodies, vaccines, and cell & gene therapies. Major industry players are continuously upgrading facilities with single-use systems, modular cleanrooms, and continuous bioprocessing platforms to increase production flexibility and reduce costs. The presence of cutting-edge innovation hubs, strong collaborations between academia and industry, and significant investment in next-generation therapies ensures that North America remains the largest and most technologically advanced market for bioprocessing equipment globally.

Asia-Pacific (Fastest-Growing Region)

Asia-Pacific is the fastest-growing region, driven by rapid expansion of biomanufacturing capabilities in China, India, South Korea, and Singapore. Governments are investing heavily in biotech infrastructure, encouraging local biologics production, and attracting global CDMOs. The region is experiencing rising adoption of single-use systems, modular facilities, and biosimilar manufacturing platforms, making it a major future growth hub. Lower production costs and a strong talent pool further support its accelerated growth.

Europe (Strong, Established Market)

Europe holds a significant share of the market, supported by its strong biopharma industry, advanced R&D infrastructure, and strict regulatory standards. Countries like Germany, the UK, Switzerland, and Ireland host major biologics manufacturing clusters. Europe’s focus on sustainability, continuous bioprocessing, and high-quality purification systems drives steady investment. While not growing as fast as Asia-Pacific, Europe remains a technologically advanced and stable market.

Latin America (Emerging Market)

Latin America is gradually expanding, with countries like Brazil and Mexico investing in biologics production and vaccine manufacturing post-COVID. Market growth is slower due to limited infrastructure and skilled workforce constraints, but increasing government initiatives and partnerships with global biopharma companies are helping accelerate regional activity.

Middle East & Africa (Early-Stage Market)

The Middle East & Africa region is at an early stage, with growth led by countries such as the UAE, Saudi Arabia, and South Africa. The region is witnessing rising interest in biotechnology, biomanufacturing training, and centralized health initiatives. However, adoption of advanced bioprocessing equipment remains limited, mainly due to high costs and fewer local production facilities.

Competitive Landscape:

Some of the leading market players operating in the global bioprocessing equipment market are Thermo Fisher Scientific, Sartorius AG, Danaher Corporation / Cytiva, Merck KGaA, and Eppendorf AG. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Recent Developments:

• In September 2025, Thermo Fisher Scientific completed a $4.0 billion acquisition of Solventum’s Purification & Filtration business. This strengthens Thermo Fisher’s bioprocessing portfolio by adding advanced filtration and membrane technologies used in both upstream and downstream workflows.
• Danaher has fully integrated its Cytiva and Pall units to create a combined “Biotechnology Group” under the well-known Cytiva brand. The merged entity offers a wider, complementary portfolio, including bioreactors (Xcellerex), filtration, chromatography (ÄKTA), and single-use systems, which enhances Cytiva’s capacity to serve end-to-end bioprocessing needs.
• In 2025, Repligen (known for filtration / single-use bioprocessing technologies) entered into a strategic partnership with Novasign, an Austrian biotech software firm. The collaboration integrates Novasign’s machine-learning and digital twin capabilities into Repligen’s tangential flow filtration (TFF) systems, enabling real-time predictive control, process optimization, and smarter PAT (process analytical technology) workflows.
• Indian CDMO Syngene International bought its first U.S. biologics manufacturing facility (formerly owned by Emergent BioSolutions) for US$36.5 million. This acquisition will scale up Syngene’s single-use bioreactor capacity from ~20,000 L to ~50,000 L, supporting growth in large-molecule manufacturing.

Key Companies:

• Thermo Fisher Scientific
• Sartorius AG
• Danaher Corporation / Cytiva
• Merck KGaA
• Eppendorf AG
• Getinge AB
• Applikon Biotechnology
• Bio-Rad Laboratories
• Solaris Biotechnology Srl
• ABEC, Inc.
• Others

Key Questions Answered by Bioprocessing Equipment Market Report

• Global bioprocessing equipment market forecasts from 2025-2030
• Regional market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2025-2030 covering 15 major countries from the regions as mentioned above
• Bioprocessing equipment submarket forecasts from 2025-2030 covering the market by product type, process, application, end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level bioprocessing equipment markets from 2025-2030
• Competitive Landscape and market positioning of top 10 players operating in the market